Relic Technologies Reports Mixed Q2 Results, Plans to Strike Off Non-Operative Subsidiary
Relic Technologies Limited announced its Q2 FY2026 results with standalone net profit of Rs 17.52 crore, up from Rs 9.75 crore in the previous quarter. However, consolidated operations showed a net loss of Rs 2.30 crore. The company plans to voluntarily strike off its non-operative subsidiary, Relic Pharma Limited, by March 31, 2026. Relic Technologies' paid-up equity share capital increased to Rs 515 crore from Rs 360 crore. The financial results were reviewed by D. Kothary & Co., who provided an unmodified opinion.

*this image is generated using AI for illustrative purposes only.
Relic Technologies Limited (BSE: 511712) has announced its unaudited financial results for the quarter ended September 30, 2025, revealing a mixed performance across its standalone and consolidated operations. The company also disclosed plans to voluntarily strike off its non-operative subsidiary, Relic Pharma Limited.
Financial Highlights
Standalone Performance
- Net profit for Q2 stood at Rs 17.52 crore, up from Rs 9.75 crore in the previous quarter.
- Total income for the quarter was Rs 34.81 crore.
- For the half-year, net profit reached Rs 19.19 crore.
Consolidated Performance
- The company reported a consolidated net loss of Rs 2.30 crore for Q2.
- Half-yearly consolidated operations showed a net loss of Rs 353.39 crore.
Key Financial Metrics
| Particulars (in Rs crore) | Q2 FY2026 (Standalone) | Q2 FY2026 (Consolidated) |
|---|---|---|
| Revenue from Operations | Not specified | 59.77 |
| Other Income | 34.81 | 20.23 |
| Total Income | 34.81 | 80.00 |
| Net Profit/(Loss) | 17.52 | (2.30) |
Subsidiary Strike-Off Plans
The Board of Directors has approved the voluntary striking off of its non-operative subsidiary, Relic Pharma Limited. Key points regarding this decision include:
- Relic Pharma Limited had nil turnover and a negligible net worth of Rs 1.019 lakh.
- The strike-off process is expected to be completed by March 31, 2026, subject to regulatory approval.
- This move aligns with the company's strategy to streamline its operations and focus on core business activities.
Capital Structure Update
Relic Technologies' paid-up equity share capital increased to Rs 515 crore from Rs 360 crore, indicating a significant capital infusion or possible bonus issue.
Audit Review
The financial results were reviewed by the company's auditors, D. Kothary & Co., who provided an unmodified opinion, lending credibility to the reported figures.
Investor Considerations
While the standalone results show improvement, the consolidated performance indicates challenges within the group. Investors should note the following:
- The stark difference between standalone and consolidated results suggests varying performances across the company's subsidiaries.
- The decision to strike off Relic Pharma Limited may impact future consolidated results by eliminating a non-performing entity.
- The increase in paid-up capital could provide the company with additional resources for growth or debt reduction.
As Relic Technologies navigates through these mixed results and structural changes, stakeholders will be watching closely to see how these developments translate into long-term value creation and improved financial health across the group.






























